Based on the experimental results of Bob t li et al., Solange Peters conducted a multicenter, single-group trial (trial registration NCT02289833) to investigate the efficacy and safety of T-DM1 in patients previously treated for HER2-overexpressing metastatic NSCLC (Peters et al., 2019). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.